Abstract | BACKGROUND: OBJECTIVE: The aim of our current study was to perform a systematic review and meta-analysis of all randomized controlled trials (RCTs) assessing the effect and safety of anacetrapib in the treatment of dyslipidemia. METHODS: We systematically searched PubMed, Embase, and Cochrane Library database from their inception to 5 October 2017, with the terms: ' anacetrapib' and 'placebo'. From 287 initial citations, 10 studies including 34781 patients with dyslipidemia were included in the final systematic review and meta-analysis. RESULTS: Pooled results showed that anacetrapib significantly increased high density lipoprotein cholesterol (HDL-C) [weighted mean differences (WMD) 53.07, 95% confidence interval (95% CI) 46.79 to 59.36] and apolipoprotein AI (ApoAI) (WMD 53.44, 95% CI 45.72 to 61.16). Our study also showed that anacetrapib significantly reduced low density lipoprotein cholesterol ( LDL-C) (WMD -32.99; 95% CI -37.13 to -28.86), Non-HDL-C (WMD -39.19; 95% CI -52.22 to -26.16), triglycerides (TG) (WMD -9.97; 95% CI -10.54 to -9.41), apolipoprotein B ( ApoB) (WMD -22.55; 95% CI -28.56 to -16.54) and lipoprotein a [LP(a)] (WMD -13.35; 95% CI -18.31 to -8.39). Our results demonstrated that there was no significant difference in all the following adverse events between the anacetrapib group and placebo group: [hepato-toxicity (OR 0.90, 95% CI: 0.75 to 1.07); musculoskeletal injury (OR 1.01, 95% CI: 0.88 to 1.15); drug-related adverse event (OR 1.00, 95% CI: 0.96 to 1.05); drug-related withdrawn (OR 1.01, 95% CI: 0.95 to 1.08)]. CONCLUSIONS: Although further studies are needed, our findings clearly offer support to the use of anacetrapib in the clinical management of patients with dyslipidemia.
|
Authors | Junteng Zhou, Qi Zhang, Yushu Wang, Peijuan Gao, Decai Chen |
Journal | Postgraduate medicine
(Postgrad Med)
Vol. 130
Issue 1
Pg. 129-136
(Jan 2018)
ISSN: 1941-9260 [Electronic] England |
PMID | 29135318
(Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
|
Chemical References |
- Anticholesteremic Agents
- Oxazolidinones
- anacetrapib
|
Topics |
- Anticholesteremic Agents
(therapeutic use)
- Dyslipidemias
(drug therapy)
- Humans
- Oxazolidinones
(therapeutic use)
|